The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study - PubMed (original) (raw)

. 2020 Jun;44(3):405-413.

doi: 10.4093/dmj.2020.0105. Epub 2020 May 21.

Yin Young Lee 1, Eunyeong Ha 1, Ji Sung Yoon 1, Kyu Chang Won 1, Hyoung Woo Lee 1, Jian Hur 2, Kyung Soo Hong 3, Jong Geol Jang 3, Hyun Jung Jin 3, Eun Young Choi 3, Kyeong Cheol Shin 3, Jin Hong Chung 3, Kwan Ho Lee 3, June Hong Ahn 4, Jun Sung Moon 5

Affiliations

The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study

Seung Min Chung et al. Diabetes Metab J. 2020 Jun.

Abstract

Background: To determine the role of diabetes mellitus (DM) in the coronavirus disease 2019 (COVID-19), we explored the clinical characteristics of patients with DM and compared risk factors such as age, glycemic control, and medications to those without DM.

Methods: This was a retrospective cohort study of 117 confirmed patients with COVID-19 which conducted at a tertiary hospital in Daegu, South Korea. The primary outcome was defined as the severe and critical outcome (SCO), of which the composite outcomes of acute respiratory distress syndrome, septic shock, intensive care unit care, and 28-day mortality. We analyzed what clinical features and glycemic control-related factors affect the prognosis of COVID-19 in the DM group.

Results: After exclusion, 110 participants were finally included. DM patients (_n_=29) was older, and showed higher blood pressure compared to non-DM patients. DM group showed higher levels of inflammation-related biomarkers and severity score, and highly progressed to SCO. After adjustment with other risk factors, DM increased the risk of SCO (odds ratio [OR], 10.771; P<0.001). Among the DM patients, SCO was more prevalent in elderly patients of ≥70 years old and age was an independent risk factor for SCO in patients with DM (OR, 1.175; _P_=0.014), while glycemic control was not. The use of medication did not affect the SCO, but the renin-angiotensin system inhibitors showed protective effects against acute cardiac injury (OR, 0.048; _P_=0.045).

Conclusion: The COVID-19 patients with DM had higher severity and resulted in SCO. Intensive and aggressive monitoring of COVID-19 clinical outcomes in DM group, especially in elderly patients is warranted.

Keywords: Aged; COVID-19; Diabetes mellitus; Prognosis; Risk factors; Severe acute respiratory syndrome coronavirus 2.

Copyright © 2020 Korean Diabetes Association.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1

Fig. 1. Patient selection. COVID-19, coronavirus disease 2019; DM, diabetes mellitus.

Fig. 2

Fig. 2. Diabetes mellitus (DM) and age as a risk factor for severe and critical outcomes in patients with coronavirus disease 2019. Severe and critical outcomes: composite outcome of acute respiratory distress syndrome, septic shock, intensive care unit care, and mortality within 28 days. Multivariate logistic regression analysis was adjusted by (A) age (<70:≥70 years old), sex, smoking status, and the presence of comorbidities (diabetes mellitus, hypertension, chronic lung disease, and malignancy) in the total number of patients and (B) age (continuous), sex, smoking status, and glycosylated hemoglobin (HbA1c), and serum glucose levels among diabetic patients. The odds ratios (ORs) are presented in log10. CI, confidence interval.

Fig. 3

Fig. 3. Effects of (A) metformin and (B) RAS inhibitors on severe and critical outcomes, acute cardiac injury, and acute kidney injury in diabetic patients with coronavirus disease 2019. Severe and critical outcomes: composite outcome of acute respiratory distress syndrome, septic shock, intensive care unit care, and mortality within 28 days. Multivariate logistic regression analysis was adjusted by age, sex, smoking status, and glycosylated hemoglobin level. The odds ratios (ORs) are presented in log10. CI, confidence interval.

Comment in

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24; doi: 10.1001/jama.2020.2648. [Epub] - DOI - PubMed
    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. - PubMed
    1. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care. 2007;30:2251–2257. - PubMed
    1. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28:810–815. - PubMed

Publication types

MeSH terms

LinkOut - more resources